| | Treatment | Patients, n (%) | Median (Q1, Q3) daily dose | | Unadjusted (mg LED/day) | Adjusted by body weighta (mg LED/kg/day) |
| | Any PD drug | 3482 (86.4) | 634.8 (360.0, 1089.5) | 13.7 (7.5, 23.7) | | Levodopa | | Levodopa ± DCI | 2982 (74.0) | 418.2 (219.2, 712.5) | 9.0 (4.6, 15.7) | | Entacaponeb | 843 (20.9) | 680.8 (399.0, 1152.2) | 14.5 (8.6, 24.2) | | Ergot dopamine agonists | | Bromocriptine | 65 (1.6) | 65.1 (29.5, 140.1) | 1.2 (0.7, 2.5) | | Pergolide | 86 (2.1) | 60.5 (25.0, 127.2) | 1.4 (0.7, 2.9) | | Cabergoline | 93 (2.3) | 97.0 (42.8, 181.6) | 2.4 (0.9, 3.7) | | Nonergot dopamine agonists | | Talipexole | 0 (0.0) | | | | Pramipexole, regular | 371 (9.2) | 94.7 (37.5, 204.3) | 2.1 (0.8, 4.6) | | Pramipexole, slow release | 270 (6.7) | 184.4 (66.2, 390.0) | 3.7 (1.3, 7.4) | | Ropinirole, regular | 181 (4.5) | 86.8 (26.9, 162.0) | 1.7 (0.6, 3.9) | | Ropinirole, slow release | 304 (7.6) | 117.9 (35.6, 266.7) | 2.4 (0.8, 5.6) | | Rotigotine | 952 (23.6) | 179.6 (96.4, 327.9) | 3.9 (2.0, 7.4) | | Apomorphine | 50 (1.2) | 38.8 (14.3, 133.3) | 0.7 (0.3, 2.3) | | Monoamine oxidase type B inhibitors | | Rasagiline | 2 (0.1) | 152.9 (75.9, 230.0) | 3.4 (1.6, 5.1) | | Selegiline | 493 (12.2) | 41.4 (21.9, 76.1) | 0.8 (0.4, 1.7) | | Anticholinergics | | Trihexyphenidyl | 6 (0.2) | | | | Biperiden | 23 (0.6) | | | | Promethazine | 8 (0.2) | | | | Piroheptine | 0 (0.0) | | | | Profenamine | 1 (0.0) | | | | Other PD drugs | | Amantadine | 540 (13.4) | 103.0 (52.1, 180.1) | 2.3 (1.2, 4.0) | | Zonisamide | 662 (16.4) | | | | Droxidopa | 521 (12.9) | | | | Istradefylline | 466 (11.6) | | |
|
|
aCalculated in patients who had body weight data available. bEntacapone or the combination drug of entacapone + levodopa/carbidopa. DCI, decarboxylase inhibitor; LED, levodopa equivalent dose; PD, Parkinson’s disease; Q1/Q3, quartile 1/quartile 3.
|
